MAPT and Alzheimer disease: Our results, which converge with reports that [18F]PI-2620 SUVRs can continue to increase until 180 min post-injection without stabilization for some AD participants with presumably the highest levels of tau (Bullich et al., 2020;Mueller et al., 2020), highlight the importance of adjusting for protocol differences to combine datasets.